A study in The Lancet Oncology shows that blood tests detecting circulating tumor DNA (ctDNA) can predict melanoma recurrence. Patients with ctDNA before treatment were more likely to relapse and did so faster. Regular ctDNA monitoring could become a vital, noninvasive tool for tracking melanoma and personalizing treatment.